ERLEADA® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option, Now Available in the U.S.
The Pharma Data
APRIL 4, 2023
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA ® (apalutamide) in the United States. Both tablet strengths are available via prescription through existing specialty pharmacy networks. FDA approval for mCSPC in September 2019.To
40 
Let's personalize your content